安旭生物
(688075)
| 流通市值：36.02亿 | | | 总市值：36.02亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 541,757,316.61 | 629,510,288.02 | 568,267,637.7 | 196,861,400.08 |
| 交易性金融资产 | 1,039,446,936.99 | 1,270,796,849.31 | 1,311,207,273.97 | 1,332,620,150.69 |
| 应收票据及应收账款 | 187,959,446.19 | 187,577,599.9 | 187,063,187.31 | 173,625,694.48 |
| 应收账款 | 187,959,446.19 | 187,577,599.9 | 187,063,187.31 | 173,625,694.48 |
| 预付款项 | 16,319,419.49 | 15,168,226.8 | 13,351,215.3 | 14,665,419.97 |
| 其他应收款合计 | 19,349,993.32 | 4,262,336.52 | 10,389,289.39 | 9,691,859.27 |
| 存货 | 128,583,511.36 | 138,348,997.67 | 133,342,048.57 | 126,532,631.26 |
| 其他流动资产 | 2,702,377,281.94 | 2,455,254,771.08 | 2,368,253,673.18 | 2,775,733,767.3 |
| 流动资产平衡项目 | 0 | 0 | 0 | -0.01 |
| 流动资产合计 | 4,635,793,905.9 | 4,700,919,069.3 | 4,591,874,325.42 | 4,629,730,923.04 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 16,000,000 | 16,000,000 | 6,000,000 | 6,000,000 |
| 固定资产 | 579,856,986.63 | 589,546,560.74 | 597,035,382.91 | 598,519,464.26 |
| 在建工程 | 232,668,735.8 | 197,253,504.95 | 221,852,199.62 | 179,316,696.79 |
| 使用权资产 | 4,197,663.3 | 4,793,197.86 | 5,400,881.32 | 3,994,434.53 |
| 无形资产 | 39,386,469.92 | 40,553,579.5 | 43,103,285.46 | 42,898,460.44 |
| 商誉 | 12,764,509.87 | 13,970,552.64 | - | - |
| 长期待摊费用 | 24,235,632.03 | 26,595,362.48 | 28,957,299.98 | 13,934,925.86 |
| 递延所得税资产 | 167,016,215.37 | 159,250,942.11 | 156,402,414.99 | 162,758,217.94 |
| 其他非流动资产 | 4,740,098 | 9,194,204.93 | 25,941,845.96 | 6,432,012.3 |
| 非流动资产平衡项目 | 0 | 0 | -0.01 | 0 |
| 非流动资产合计 | 1,080,866,310.92 | 1,057,157,905.21 | 1,084,693,310.23 | 1,013,854,212.12 |
| 资产总计 | 5,716,660,216.82 | 5,758,076,974.51 | 5,676,567,635.65 | 5,643,585,135.16 |
| 流动负债: | | | | |
| 短期借款 | 140,000,000 | 140,000,000 | - | 0 |
| 衍生金融负债 | - | - | 394,155.37 | - |
| 应付票据及应付账款 | 341,039,142.05 | 341,922,250.3 | 382,911,315.37 | 353,224,874.4 |
| 其中：应付票据 | 81,787,490.37 | 106,489,121.72 | 88,929,983.5 | 74,322,339 |
| 应付账款 | 259,251,651.68 | 235,433,128.58 | 293,981,331.87 | 278,902,535.4 |
| 预收款项 | - | - | - | 0 |
| 合同负债 | 14,013,482.3 | 16,043,427.16 | 10,384,896.51 | 14,910,991.23 |
| 应付职工薪酬 | 12,679,560.18 | 13,666,131.73 | 18,905,602.73 | 11,374,288.37 |
| 应交税费 | 7,574,598.34 | 10,392,206.76 | 6,202,149.84 | 5,110,524.55 |
| 其他应付款合计 | 107,849,599.1 | 5,714,952.41 | 14,364,360.84 | 11,120,066.97 |
| 应付股利 | 101,128,692.8 | - | - | - |
| 一年内到期的非流动负债 | 3,393,044.22 | 509,374.35 | 3,439,228.17 | 3,319,887.29 |
| 其他流动负债 | - | 1,528,990.14 | 539,028.49 | 0 |
| 流动负债平衡项目 | 0 | 0 | 0 | -0.01 |
| 流动负债合计 | 626,549,426.19 | 529,777,332.85 | 437,140,737.32 | 399,060,632.8 |
| 非流动负债: | | | | |
| 租赁负债 | 2,275,699.16 | 5,023,786.58 | 2,105,441.07 | 2,972,496.39 |
| 预计负债 | - | - | - | 1,742,922.53 |
| 递延收益 | 5,460,460.27 | 7,172,589.71 | 7,164,431.36 | 7,544,805.11 |
| 递延所得税负债 | 63,610,929.77 | 69,617,290.3 | 69,573,957.22 | 73,522,535.81 |
| 其他非流动负债 | - | 7,137.18 | - | - |
| 非流动负债合计 | 71,347,089.2 | 81,820,803.77 | 78,843,829.65 | 85,782,759.84 |
| 负债平衡项目 | 0 | 0.01 | 0 | 0 |
| 负债合计 | 697,896,515.39 | 611,598,136.63 | 515,984,566.97 | 484,843,392.64 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 127,082,805 | 127,082,805 | 127,082,805 | 127,082,805 |
| 资本公积 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 |
| 减:库存股 | 24,325,773.2 | - | - | - |
| 其他综合收益 | -1,151,374.97 | 874,014.22 | 4,624,033.91 | 7,684,413.74 |
| 盈余公积 | 62,557,185.3 | 64,291,183.82 | 62,557,185.3 | 62,069,454.51 |
| 未分配利润 | 3,808,238,706.56 | 3,907,914,726.66 | 3,920,008,742.45 | 3,915,433,775.24 |
| 归属于母公司股东权益平衡项目 | 0.01 | 0 | -0.01 | 0 |
| 归属于母公司股东权益合计 | 5,022,735,272.97 | 5,150,496,453.97 | 5,164,606,490.92 | 5,162,604,172.76 |
| 少数股东权益 | -3,971,571.54 | -4,017,616.08 | -4,023,422.24 | -3,862,430.24 |
| 股东权益合计 | 5,018,763,701.43 | 5,146,478,837.89 | 5,160,583,068.68 | 5,158,741,742.52 |
| 负债和股东权益合计 | 5,716,660,216.82 | 5,758,076,974.51 | 5,676,567,635.65 | 5,643,585,135.16 |
| 公告日期 | 2026-08-28 | 2026-04-30 | 2026-04-30 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |